Johnson & Johnson Stock Dives After Strokes Sideline Its Pulsed …

Jan 8, 2025 · Johnson & Johnson stock skidded Wednesday after the company temporarily paused sales of its pulsed field ablation system.

CouponFollow Extension

42%
OFF

Why Johnson & Johnson (JNJ) Dipped More Than Broader Market …

3 weeks from now

Oct 3, 2024 · Johnson & Johnson (JNJ) concluded the recent trading session at $160.50, signifying a -0.42% move from its prior day's close.

yahoo.com

$8
OFF

Johnson & Johnson Shares Fall After Hours On $8 Billion Jury Award

3 weeks from now

Oct 8, 2019 · Shares of drugmaker slide after Pennsylvania jury awards plaintiff huge damages tied to an anti-psychotic drug's side effects.

thestreet.com

FAQs about Johnson & Johnson Stock Dives After Strokes Sideline Its Pulsed … Coupon?

Why did Johnson & Johnson stock drop Wednesday?

Johnson & Johnson stock skidded Wednesday after the company temporarily paused sales of its pulsed field ablation system. The news is a boon for rivals Boston Scientific and Medtronic. Please watch the video at Investors.com - How To Sell Stocks: When To Cut Losses ...

What happened to Johnson & Johnson stock?

Johnson & Johnson stock has mostly fallen since early September. Boston Scientific stock jumped 4.3% to close at 95.94, though that could be related to its acquisition of Bolt Medical, also announced Wednesday. Medtronic shares popped 3.5% to 82.68. The company's Varipulse news isn't surprising, Needham's Matson said. ...

What happened to J&J stock?

J&J shares slipped 2.7%, closing at 142.27. Johnson & Johnson stock has mostly fallen since early September. Boston Scientific stock jumped 4.3% to close at 95.94, though that could be related to its acquisition of Bolt Medical, also announced Wednesday. Medtronic shares popped 3.5% to 82.68. ...

Why did Johnson & Johnson stock fall 3%?

Investing.com -- Shares of Johnson & Johnson (NYSE: JNJ) fell 3% amid concerns regarding its cardiac ablation device, Varipulse. ...

Is Johnson & Johnson's 'varipulse' news surprising?

The company's Varipulse news isn't surprising, Needham's Matson said. In Johnson & Johnson's pivotal study — the one that helped clinch Food and Drug Administration approval — three patients out of 277 experienced cerebrovascular events. That included two strokes and one transient ischemic attack. ...

Why did Johnson & Johnson pause varipulse procedures?

The report, spearheaded by analyst Larry Biegelsen, pointed to conversations with physicians and industry contacts indicating that Johnson & Johnson has possibly paused Varipulse procedures because of adverse events, including strokes. ...